RhumbLine Advisers
AQST icon

RhumbLine Advisers’s Aquestive Therapeutics AQST Stock Holding History

RhumbLine Advisers’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$620K Buy
149,046
+12,507
+9% +$52.6K ﹤0.01% 2618
2026
Q1 		$567K Buy
136,539
+3,000
+2% +$12.2K ﹤0.01% 2538
2025
Q4 		$863K Sell
133,539
-931
-0.7% -$5.8K ﹤0.01% 2317
2025
Q3 		$752K Sell
134,470
-6,402
-5% -$27.7K ﹤0.01% 2416
2025
Q2 		$466K Buy
140,872
+36,509
+35% +$105K ﹤0.01% 2723
2025
Q1 		$303K Sell
104,363
-2,594
-2% -$7.85K ﹤0.01% 2885
2024
Q4 		$381K Buy
106,957
+3,259
+3% +$15K ﹤0.01% 2835
2024
Q3 		$516K Buy
103,698
+5,861
+6% +$22.8K ﹤0.01% 2676
2024
Q2 		$254K Buy
+97,837
New +$327K ﹤0.01% 3090
2021
Q2 		– Sell
-18,815
Closed -$98K – 2987
2021
Q1 		$98K Sell
18,815
-925
-5% -$4.92K ﹤0.01% 2935
2020
Q4 		$106K Buy
19,740
+2,960
+18% +$17.7K ﹤0.01% 2963
2020
Q3 		$81K Sell
16,780
-260
-2% -$1.7K ﹤0.01% 2905
2020
Q2 		$83K Buy
+17,040
New +$78.4K ﹤0.01% 2990

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

RhumbLine Advisers's AQST Position: Q2 2026 in Review

RhumbLine Advisers increased its Aquestive Therapeutics (AQST) stake by 9.2% in Q2 2026, buying an estimated $52.6K and bringing the position to 149,046 shares worth $620K. The position accounts for ﹤0.01% of the portfolio, ranked #2618.

RhumbLine Advisers first reported a position in AQST in Q2 2020 and has held it in 13 quarters since. The position peaked at $863K in Q4 2025. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • RhumbLine Advisers held 149,046 shares of Aquestive Therapeutics worth $620K as of Q2 2026.
  • RhumbLine Advisers bought 12,507 Aquestive Therapeutics shares in Q2 2026, an estimated $52.6K.
  • Aquestive Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2618 holding.
  • RhumbLine Advisers first reported a position in Aquestive Therapeutics in Q2 2020 and has held it in 13 quarters since.
  • RhumbLine Advisers's Aquestive Therapeutics position peaked at $863K in Q4 2025.
  • 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.